--- title: "Ovid Therapeutics (OVID) news: offering and convertible notes" url: "https://aibio.space/companies/ovid-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OVID offering and convertible notes news: Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds. Ovid Therapeutics Inc." --- OVID Ovid Therapeutics Inc. NASDAQ · United States # Ovid Therapeutics (OVID) news OVID offering and convertible notes news Financings · 2025-10-03 ## [Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds](https://aibio.space/news/ovid-therapeutics-agrees-pipe-financing-80-8-million-initial-gross/) Ovid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors. ## Latest Ovid Therapeutics news 1. 2025-09-16 Listings [Ovid Therapeutics regains compliance with Nasdaq $1.00 bid price rule](https://aibio.space/news/ovid-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/) Nasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level. 2. 2025-02-13 Listings [Ovid Therapeutics gets Nasdaq minimum bid price notice, has until August 11, 2025](https://aibio.space/news/ovid-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/) Nasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now. ## Ovid Therapeutics at a glance - **Ticker**: OVID - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $117.2 million ### Related companies - [Erasca](https://aibio.space/companies/erasca/) NASDAQ: ERAS - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA - [Scopus Biopharma](https://aibio.space/companies/scopus-biopharma/) OTC: SCPS - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) NASDAQ: AYTU - [Cingulate](https://aibio.space/companies/cingulate/) NASDAQ: CING - [Vanda Pharmaceuticals](https://aibio.space/companies/vanda-pharmaceuticals/) NASDAQ: VNDA - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) NASDAQ: PTGX ### Also on NASDAQ - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) BCAX - [CERUS CORP](https://aibio.space/companies/cerus/) CERS - [Climb Bio](https://aibio.space/companies/climb-bio/) CLYM - [Bolt Biotherapeutics](https://aibio.space/companies/bolt-biotherapeutics/) BOLT - [Lumexa Imaging Holdings](https://aibio.space/companies/lumexa-imaging/) LMRI - [Black Hawk Acquisition](https://aibio.space/companies/black-hawk-acquisition/) BKHA ## What Ovid Therapeutics does Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders. Its programs seek to address fundamental biological targets in the brain implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. The company says it has in-licensed and clinically developed potential medicines that may offer first-in-class or best-in-class mechanisms of action. Its clinical programs are indicated for drug-resistant focal onset seizures, developmental and epileptic encephalopathies, including tuberous sclerosis complex seizures and infantile spasms, psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia. Its KCC2 direct activator portfolio has potential applications across psychoses and mood disorders, and the focus of its first oral program is psychosis associated with Parkinson's disease. The company estimates that approximately 50 million people globally live with epilepsy. Ovid also says it seeks to establish multiple sources of potential revenue through clinical and commercial milestones, strategic collaborations and partnerships. | Product or program | What it is | Stage | |---|---|---| | First oral program (KCC2 activator) | Oral small molecule for psychosis associated with Parkinson's disease | clinical-stage | | Focal onset seizures program | Small molecule for drug-resistant focal onset seizures | clinical-stage | | Developmental and epileptic encephalopathies program | Small molecule for DEEs, including TSC seizures and infantile spasms | clinical-stage | | Schizophrenia program | Small molecule for schizophrenia | clinical-stage | Summarised from the company's [10-K filed Mar 18, 2026](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/ovid-20251231.htm). ## Ovid Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$7.3 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | [$566,000](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | | Research and development | [$25.6 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | [$36.8 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | | Net income (loss) | [-$17.4 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | [-$26.4 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | | Cash from operations | [-$38.3 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | [-$56.0 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | | Cash and equivalents | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026056498/) | [$26.3 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | | Short-term investments | [$56.5 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026056498/) | [$26.8 million](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019438/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.3 million, plus short-term investments of $105.9 million, $117.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ovid Therapeutics Has Ovid Therapeutics raised money recently? Our latest story on this, dated Oct 3, 2025: "Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ovid-therapeutics-agrees-pipe-financing-80-8-million-initial-gross/). Has Ovid Therapeutics sold convertible notes? Our latest story on this, dated Oct 3, 2025: "Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ovid-therapeutics-agrees-pipe-financing-80-8-million-initial-gross/). What is the ticker symbol of Ovid Therapeutics? Ovid Therapeutics Inc. trades under the ticker OVID on NASDAQ. Where is Ovid Therapeutics listed? Ovid Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1OT; LS:A2DQ8S; LSX:A2DQ8S. What is the SEC CIK of Ovid Therapeutics? The SEC Central Index Key (CIK) for Ovid Therapeutics Inc. is 1636651. Its filings are on SEC EDGAR. How many shares does Ovid Therapeutics have outstanding? 195,297,857 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Ovid Therapeutics listed under? Our directory records Ovid Therapeutics Inc. under United States. What does Ovid Therapeutics do? Our directory classifies Ovid Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ovid Therapeutics? The ISIN recorded for Ovid Therapeutics Inc. is US6904691010. Does aibio.space cover Ovid Therapeutics? aibio.space lists Ovid Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ovid Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Ovid Therapeutics develop? Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders. Its programs seek to address fundamental biological targets in the brain implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. What is First oral program (KCC2 activator) from Ovid Therapeutics? First oral program (KCC2 activator): Oral small molecule for psychosis associated with Parkinson's disease Stage: clinical-stage. What is Focal onset seizures program from Ovid Therapeutics? Focal onset seizures program: Small molecule for drug-resistant focal onset seizures Stage: clinical-stage. What was Ovid Therapeutics's revenue last year? $7.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Ovid Therapeutics Members talk about Ovid Therapeutics (OVID). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ovid Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-04-20 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828026025926/ovid-20260420.htm) 2. 2026-03-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovidexhibit9912025_x10-k.htm) 3. 2025-12-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000163665125000017/ovid-20251211.htm) 4. 2025-11-07 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000114036125040884/ny20057375x3_def14a.htm) 5. 2025-10-28 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000114036125039516/ny20057375x2_pre14a.htm) 6. 2025-10-27 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000114036125039497/ny20057375x1_pre14a.htm) 7. 2025-10-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm) 8. 2025-09-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000119312525204308/d80889d8k.htm) 9. 2025-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828025040008/ovid-20250630.htm) 10. 2025-07-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/ovid-20250710.htm) 11. 2025-05-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828025027146/ovid-20250521.htm) 12. 2025-05-02 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1636651/000162828025021830/ovid-20250502.htm) 13. 2025-02-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/d385884d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OVID on TradingView](https://www.tradingview.com/symbols/NASDAQ-OVID/). ## SEC filings and registration - **SEC name**: Ovid Therapeutics Inc. - **CIK**: 1636651 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OVID (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10001 - **Phone**: 212-776-4381 - **Shares outstanding**: 195,297,857 as of 2026-08-11 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1636651/000162828026056498/ovid-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/ovid-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/ovid-20260707.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1636651/000162828026042396/ovid-20260611.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/ovid-20260602.htm) filed 2026-06-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1636651/000162828026033864/ovid-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/ovid-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1636651/000162828026027621/ovid-20260427.htm) filed 2026-04-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001636651), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ovid Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OVID, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ovid Therapeutics Inc. - **Ticker**: OVID - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6904691010 - **Other listed symbols**: GETTEX:1OT; LS:A2DQ8S; LSX:A2DQ8S - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OVID/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ovid-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ovid Therapeutics (OVID) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/ovid-therapeutics/